Home | 
What's New | 
About | 
Contact | 
Sitemap

CancerGuide: Alternative and Complementary Therapies

Evaluating Alternative Therapies
Separating The Wheat From the Chaff (will open in new window!)
Promising Therapies
+ PSK
Bovine Cartilage References
Lesser Known Therapies
Popular Therapies
Essiac
Other
Links
MedLine Search: Bovine Cartilage

Legacy MedLine Search

This MedLine Search of the technical medical literature is from the early days of CancerGuide so it may not include the latest research. The articles referenced are still relevant but more recent ones may also be available. For more information on the incredibly powerful and freely available MedLine database see my Article on Medline.

In all cases I have selected the references that looked most interesting to me. These are searches with a point of view! There could be references on this same subject that I didn't include that you would have. For both of these reasons as well as the age of the search, you may want to consider doing your own search on this subject after looking at mine.

Finally, keep in mind that the abstracts presented here are only summaries of the actual articles. If you want to delve deeper you may want to get some of these articles from a Medical Library or an online document delivery service, as is provided with all MedLine accesses (usually for a fairly substantial fee).


SUN MAR 05,1995 4:15 PM

PaperChase Contains 8,684,936 References -- All References Found in the
Following Databases of the National Library of Medicine and the National
Cancer Institute*.  You are searching all four databases simultaneously.

  Database    Indexing Began    Updated     Current through
   MEDLINE        1966          weekly       April 1995 Update, Part 3
   HEALTH         1975          monthly      March 1995 Update
   AIDSLINE       1980          monthly      December 1994 Update
  *CANCERLIT      1980          monthly      February 1995 Update


LIST                    REFERENCES   LIST                     REFERENCES
 A) CATRIX                       5    C) *SUM AB                      17
 B) PRUDDEN JF                  14


*****PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE*****

(REFERENCE 1 OF 11)
67044777

Wolarsky ER  Finke SR  Prudden JF
Acceleration of wound healing with heterologous cartilage.
  Immunological considerations.

In: Proc Soc Exp Biol Med (1966 Nov) 123(2):556-61

[No Abstract Available]


*****AMERICAN JOURNAL OF SURGERY*****

(REFERENCE 2 OF 11)
70176561

Prudden JF  Migel P  Hanson P  Friedrich L  Balassa L
The discovery of a potent pure chemical wound-healing accelerator.

In: Am J Surg (1970 May) 119(5):560-4

[No Abstract Available]

(REFERENCE 3 OF 11)
67043403

Allen J  Prudden JF
Histologic response to a cartilage powder preparation in a controlled
  human study.

In: Am J Surg (1966 Dec) 112(6):888-91

[No Abstract Available]


*****JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS*****

(REFERENCE 5 OF 11)
89036285

Rosen J  Sherman WT  Prudden JF  Thorbecke GJ
Immunoregulatory effects of catrix.

In: J Biol Response Mod (1988 Oct) 7(5):498-512

The immunoregulatory effect of Catrix on in vitro and and in vivo
  antibody production was examined in mice. Catrix, an acidic
  mucopolysaccharide complex, contains glycosaminoglycans including
  chondroitin sulfate. Catrix-S, a soluble derivative, was found to
  enhance T-dependent and T-independent antibody responses in vivo in a
  dose-dependent manner, with 100 mg intraperitoneally or 10 mg
  intravenously being optimal. Lower doses were found to be less
  effective or inhibitory. In vitro, the enhancing activity of Catrix-S
  on proliferative response was additive with that of dextran sulfate
  and lipopolysaccharide but not with chondroitin sulfate C. This
  immunoaugmenting activity appears to be related to the chondroitin
  sulfate component of Catrix-S, because both have similar effects on
  in vivo and in vitro antibody responses and because chondroitinase
  ABC inactivates activity. The inhibitory activity of Catrix-S could
  be separated from its stimulatory effects by ammonium sulfate
  precipitation or by fractionation according to molecular weight. The
  immunoaugmenting effect was present in the 0-30% saturated ammonium
  sulfate precipitate and in the 5-10,000-m.w. and 30-100,000-m.w.
  fractions. The ability of Catrix-S to enhance antibody responses in
  nude as well as in normal mice, and antibody responses to T-
  independent as well as to T-dependent antigens, indicates that its
  activity is due in part to a direct effect on B cells and/or to an
  indirect effect mediated by macrophages.

Institutional address:
     Department of Pathology
     New York University Medical Center
     New York.

(REFERENCE 6 OF 11)
86114125

Durie BG  Soehnlen B  Prudden JF
Antitumor activity of bovine cartilage extract (Catrix-S) in the
  human tumor stem cell assay.

In: J Biol Response Mod (1985 Dec) 4(6):590-5

Catrix is an acidic mucopolysaccharide complex derived from bovine
  tracheal cartilage. The antitumor efficacy of Catrix has been
  evaluated in the human tumor stem cell assay system using three human
  tumor cell lines and fresh biopsy specimens from 22 patients with
  malignant tumors. In vitro efficacy has been demonstrated with high
  dose continuous exposure Catrix, particularly against the 8226 human
  myeloma cell line as well as ovarian, pancreatic, colon, testicular,
  and sarcoma biopsy specimens. The level of sensitivity was at less
  than or equal to 30% survival of colony growth in vitro. Since the in
  vitro concentrations may be achievable in vivo, the results justify
  more detailed in vitro evaluation as well as potential clinical
  trials.

Institutional address:
     Department of Internal Medicine
     University of Arizona Health Sciences Center
     Tucson 85724.

(REFERENCE 7 OF 11)
86114124

Romano CF  Lipton A  Harvey HA  Simmonds MA  Romano PJ  Imboden SL
A phase II study of Catrix-S in solid tumors.

In: J Biol Response Mod (1985 Dec) 4(6):585-9

Catrix-S is an acidic mucopolysaccharide complex derived from bovine
  tracheal cartilage. This material was administered by weekly
  subcutaneous injection (5.0-7.5 g/week) to nine patients with
  progressive metastatic malignancy. One complete response was seen in
  a patient with metastatic renal cell carcinoma to the lungs. Eight
  patients had progression of their disease. No undue toxicity and no
  consistent immunologic alteration was noted.

Institutional address:
     Department of Medicine
     Milton S. Hershey Medical Center
     Pennsylvania State University
     Hershey 17033.

(REFERENCE 8 OF 11)
86114123

Prudden JF
The treatment of human cancer with agents prepared from bovine
  cartilage.

In: J Biol Response Mod (1985 Dec) 4(6):551-84

Oral and subcutaneous administration of specific preparations of
  bovine tracheal cartilage rings (Catrix), a nontoxic agent, has
  resulted in a high response rate in 31 cases of a variety of clinical
  malignancies (response rate 90%, 61% complete). The demonstrated
  responder include present therapeutic disasters such as glioblastoma
  multiforme and cancers of the pancreas and lung. Other types which
  were treated with success included cancers of the ovary, rectum,
  prostate, cervix, thyroid, and an inoperable squamous cancer of the
  nose. These responses were observed when full dose therapy was given
  over prolonged courses of treatment (years). This wide range of
  Catrix efficacy now invites investigation by others to confirm the
  effectiveness of the material and to isolate the molecular entities
  responsible for these unexpectedly favorable results.

Institutional address:
     Department of Surgery
     Doctors Hospital
     New York
     New York.


*****PROCEEDINGS, ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL*****

(REFERENCE 9 OF 11)
94600764

Puccio C  Mittelman A  Chun H  Baskind P  Ahmed T
Treatment of metastatic renal cell carcinoma with Catrix (Meeting
  abstract).

In: Proc Annu Meet Am Soc Clin Oncol (1994) 13:A769 1994

Catrix is an acidic mucopolysaccharide complex derived from bovine
  tracheal cartilage which has demonstrated immunostimulatory and anti-
  mitotic activity in both in vitro and in vivo models. Formulations
  include an injectable 5% solution and oral capsule 375 mg. Four
  different schedules were evaluated in patients (pts) with metastatic
  renal cell carcinoma. Of the 35 pts enrolled, 22 were evaluable for
  response (completing greater than 3 mo of therapy). Results are shown
  in a table. Ten of the 22 evaluable pts were not previously treated
  with any systemic therapy; all 3 responders (and 1 SD) occurred in
  the subset of untreated pts. Lungs were the major site of response
  with disappearance of lesions (2) and greater than 50% shrinkage (1);
  minor responses noted in liver (1) and kidney (1). Duration of
  response is 30+ mo, 12+ mo and 6+ mo in the 3 PRs. Toxicity was mild
  (Grade I) and included dysgeusia (8), fatigue (3), dyspepsia (2),
  nausea (2), fever (2), dizziness (1), and scrotal edema (1). Our
  results suggest that Catrix is very well tolerated and may be active
  in previously untreated pts with metastatic renal cell carcinoma.
  Further accrual of pts is warranted.

Institutional address:
     New York Medical College
     Valhalla
     NY 10595


*****SEMINARS IN ARTHRITIS AND RHEUMATISM*****

(REFERENCE 10 OF 11)
74168980

Prudden JF  Balassa LL
The biological activity of bovine cartilage preparations. Clinical
  demonstration of their potent anti-inflammatory capacity with
  supplementary notes on certain relevant fundamental supportive
  studies.

In: Semin Arthritis Rheum (1974 Summer) 3(4):287-321

[No Abstract Available]


*****SURGERY, GYNECOLOGY AND OBSTETRICS*****

(REFERENCE 11 OF 11)
67167476

Prudden JF  Wolarsky E
The reversal by cartilage of the steroid-induced inhibition of wound
  healing.

In: Surg Gynecol Obstet (1967 Jul) 125(1):109-13

[No Abstract Available]




Home | 
What's New | 
About | 
Contact | 
Sitemap


This CancerGuide Page By Steve Dunn. © Steve Dunn
Page Created: 1995, Last Updated: